

## TABLE OF CONTENTS

	<b>Page</b>
<b>ACKNOWLEDGEMENT</b>	iii
<b>ABSTRACT (IN ENGLISH)</b>	v
<b>ABSTRACT (IN THAI)</b>	viii
<b>TABLE OF CONTENTS</b>	xi
<b>LIST OF TABLES</b>	xxiii
<b>LIST OF FIGURES</b>	xxvii
<b>ABBREVIATIONS AND SYMBOLS</b>	xxxiv
<b>CHAPTER 1 INTRODUCTION</b>	1
<b>CHEPTER 2 LITERATURE REVIEW</b>	
1. Viruses	4
2. Human herpesviruses	4
3. Herpes simplex virus	7
3.1 Background and biological properties	7
3.2 Structure properties of herpes simplex virus	8
Viral genome	9
An icosahedral capsid	10
A tegument	11
Envelope	11
4. Herpes simplex virus infection	12
Initial infection	12

**TABLE OF CONTENTS (continued)**

	<b>Page</b>
Latent infection	13
Reactivation and recurrent infection	14
5. Herpes simplex virus attachment and entry	17
6. Replication and expression of herpes simplex viral DNA	22
7. Virion assemble and release	26
8. Pathogenesis and immunity	29
9. Transmission and disease of HSV	35
Oral herpes	37
Herpetic gingivostomatitis	38
Herpes pharyngitis	38
Herpes stomatitis	38
Herpes keratitis and HSV keratoconjunctivitis	38
Herpetic whitlow	39
Eczema herpeticum	39
Genital herpes	40
HSV meningitis and encephalitis	41
HSV infection in the neonate and newborn	42
10. Laboratory diagnosis	42
10.1 Cytology technique	43
10.2 Serological assays	43
10.3 Molecular method	44

**TABLE OF CONTENTS (continued)**

	<b>Page</b>
11. Prevention of HSV infection	44
11.1 Acyclovir	46
11.2 Famciclovir (Famvir)	47
11.3 Valacyclovir	47
11.4 Penciclovir	47
11.5 Cidofovir	48
11.6 Foscarnet	48
12. Antiviral agent from medicinal plants	49
Extraction method of medicinal plants	50
13. Phytochemicals	53
13.1 Flavonoids	53
13.2 Alkaloids	53
13.3 Saponins	53
13.4 Tannin	54
13.5 Anthraquinones	54
13.6 Cardiac glycosides	54
13.7 Phenolic compounds	54
13.8 Coumarins	55
14. Antiviral activities of some medicinal plant extracts	55
15. Plants used in this study and description	57
15.1 <i>Andrographis paniculata</i> (Burm.f.) Wall. ex Nees	58

**TABLE OF CONTENTS (continued)**

	<b>Page</b>
15.2 <i>Cissus quadrangularis</i> L.	59
15.3 <i>Coscinium fenestratum</i> (Gaertn.) Colebr.	60
15.4 <i>Croton roxburghii</i> N.P. Balakr.	61
15.5 <i>Derris scandens</i> (Roxb.) Benth.	62
15.6 <i>Eclipta prostrata</i> (L.) L.	63
15.7 <i>Glycyrrhiza glabra</i> (L.)	64
15.8 <i>Gynostemma pentaphyllum</i> (Thunb.) Makino	65
15.9 <i>Houttuynia cordata</i> Thunb.	66
15.10 <i>Leptochloa chinensis</i> (L.) Nees	67
15.11 <i>Momordica charantia</i> Linn.	68
15.12 <i>Phyllanthus amarus</i> Schum.&Thonn.	69
15.13 <i>Pluchea indica</i> (Linn.) Less.	70
15.14 <i>Pseuderatherum platiferum</i> (Wall.) Radlk. ex. Lindau.	71
15.15 <i>Rhinacanthus nasutus</i> (Linn.) Kurz	72
15.16 <i>Schefflera leucantha</i> R.Vig.	73
15.17 <i>Senna alata</i> (Linn.) Roxb.	74
15.18 <i>Sphenodesme</i> sp.	75
15.19 <i>Stemona tuberosa</i> Lour.	76
15.20 <i>Stephania venosa</i> (Blume) Spreng.	77
15.21 <i>Thunbergia laurifolia</i> Lindl.	78

**TABLE OF CONTENTS (continued)**

	<b>Page</b>
15.22 <i>Tinospora crispa</i> (Linn.) Miers ex Hook.f. & Thomson	79
15.23 <i>Zingiber montanum</i> (Koenig) Linkex Dietr.	80
<b>CHEPTER 3 METERIALS AND METHODS</b>	
1. Medicinal plants	81
2. Extraction of medicinal plants	84
3. Anti-herpes simplex virus assay	84
3.1 Cell culture	84
3.2 Herpes simplex virus	85
3.3 Acyclovir	85
3.4 Plaque titration assay	86
3.5 Cell cytotoxicity	86
3.6 Plaque reduction assay	87
3.7 Mechanism of medicinal plant extracts on HSV inhibition	87
3.7.1 Inactivation kinetic	87
3.7.2 Effect of medicinal plant extracts on HSV before viral attachment	88
3.7.3 Effect of medicinal plant extracts on HSV during viral attachment	88

**TABLE OF CONTENTS (continued)**

	<b>Page</b>
3.7.4 Effect of medicinal plant extracts on HSV after viral attachment	89
3.7.5 Effect of medicinal plant extracts on HSV multiplication	90
3.7.6 Effect of medicinal plant extracts on HSV DNA	90
3.7.6.1 Viral DNA extraction	90
3.7.6.2 Detection of viral DNA by agarose gel electrophoresis	92
3.7.7 Effect of medicinal plant extracts on HSV protein	93
3.7.7.1 Preparation of HSV infected cell	93
3.7.7.2 Extraction of HSV protein	93
3.7.7.3 Determination of HSV protein by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE)	94
3.7.7.4 Detection of HSV protein by Western blot analysis	95
4. Separation and partial purification of medicinal plant extracts	96
4.1 Separation of medicinal plant extracts by partition technique	96

**TABLE OF CONTENTS (continued)**

	<b>Page</b>
4.2 Column chromatography	97
4.2.1 Isolation of <i>E. prostrata</i>	97
4.2.2 Isolation of <i>Sphenodesme</i> sp.	98
4.3 Thin layer chromatography (TLC)	99
5. Determination of phytochemical compounds in the medicinal plant extracts	100
5.1 Detection of alkaloids	100
5.2 Detection of anthraquinon glycoside	101
5.3 Detection of cardiac glycoside	101
5.4 Detection of coumarin	102
5.5 Detection of flavonoids	102
5.6 Detection of phenolic compound	103
5.7 Detection of saponins	103
5.8 Detection of tannin	103
6. Chromatographic fingerprint of plant extract	104
6.1 Gas chromatography/Mass spectrometry assay (GC/MS)	105
6.2 High performance liquid chromatography (HPLC)	105
7. Development of herbal gel product for treatment of HSV infection	105
7.1 Stability test of herbal gel product	106

**TABLE OF CONTENTS (continued)**

	<b>Page</b>
8. Statistical analysis	107
<b>CHEPTER 4 RESULTS AND DISCUSSION</b>	
1. Medicinal plant	108
2. Extraction of medicinal plants	108
3. Cytotoxicity of medicinal plant extract by cell viability assay	113
4. Plaque titration assay of virus	120
5. Inhibitory effect of acyclovir (ACV) against HSV-1F and HSV-2G infection	120
6. Determination of activity of medicinal plant extracts against HSV-1F and HSV-2G infection by plaque reduction assay	122
7. Mechanism of medicinal plant extracts on inhibition of HSV infection	130
7.1 Effect of medicinal plant extracts on HSV when treatment the extracts before viral attachment	130
7.2 Effect of medicinal plant extracts on HSV when treatment the extracts during viral attachment	135
7.3 Effect of medicinal plant extracts on HSV when treatment after viral attachment	139
7.4 Inactivation kinetics	142



**TABLE OF CONTENTS (continued)**

	<b>Page</b>
7.5 Effect of plant extracts on HSV multiplication	153
7.6 Effect of medicinal plant extracts on viral DNA	163
7.7 Effect of medicinal plant extracts on viral protein synthesis	169
8. Separation and partial purification of medicinal plant extracts	179
8.1 Separation of <i>E. prostrata</i>	180
8.1.1 Separation of <i>E. prostrata</i> extracts by partition technique	180
8.1.2 Cytotoxicity of partial purified fraction isolated from ethanolic extract of <i>E. prostrata</i> on Vero cell	181
8.1.3 Antiviral activity of partial purified fractions isolated from <i>E. prostrata</i> by plaque reduction assay	182
8.1.4 Column chromatography of <i>E. prostrata</i>	185
8.1.5 TLC screening of <i>E. prostrata</i> after separation by column chromatography	187
8.1.6 Cytotoxicity of <i>E. prostrata</i> fractions isolated from column chromatography on Vero cell	188

**TABLE OF CONTENTS (continued)**

	<b>Page</b>
8.1.7 Antiviral activity by <i>E. prostrata</i> fraction isolated from column chromatography	190
8.2 Separation of <i>Sphenodesme</i> sp.	192
8.2.1 Separation of <i>Sphenodesme</i> sp. extracts by partition technique	192
8.2.2 Cytotoxicity of partial purified fraction isolated from ethanolic extract of <i>Sphenodesme</i> sp. on Vero cell	193
8.2.3 Antiviral activity of partial purified fractions isolated from <i>Sphenodesme</i> sp. by plaque reduction assay	194
8.2.4 Isolation of bioactive fraction from ethanolic extract of <i>Sphenodesme</i> sp. by column chromatography	196
8.2.5 TLC screening of partition technique	198
8.2.6 Cytotoxicity of <i>Sphenodesme</i> sp. fractions isolated from column chromatography on Vero cell by cell cytotoxicity	199
8.2.7 Antiviral activity by <i>Sphenodesme</i> sp. fractions isolated from column chromatography	201

**TABLE OF CONTENTS (continued)**

	<b>Page</b>
8.2.8 Isolation of P107 fraction from ethanolic extract of <i>Sphenodesme</i> sp. by column chromatography	204
8.2.9 Cytotoxicity of <i>Sphenodesme</i> sp. fractions isolated from column chromatography on Vero cell	206
8.2.10 Antiviral activity by fractions isolated from P107 by column chromatography	207
9. Preliminary determination of phytochemical groups	209
9.1 Chromatographic fingerprint of ethanolic extracts of <i>Sphenodesme</i> sp. and P107-03	214
9.1.1 Chromatographic fingerprint by gas chromatography/Mass spectrometry assay (GC-MS)	214
9.1.2 Chromatographic fingerprint of plant extracts by High performance liquid chromatography (HPLC)	216
10. Development of gel product for treatment of HSV infection	219
10.1 Herbal gel product preparation	219
10.2 Cytotoxicity of herbal gel product	221

**TABLE OF CONTENTS (continued)**

	<b>Page</b>
10.3 Stability test of herbal gel product	221
10.3.1 Short-term determination of herbal gel stability after heating-cooling cycle	222
10.3.2 Long-term determination of herbal gel stability	226
10.3.2 Study on irritation of herbal gel product	236
<b>CHAPTER 5 CONCLUSION</b>	239
<b>REFERENCES</b>	244
<b>APPENDICES</b>	
<b>APPENDIX A</b> Media and reagents for cells culture: Vero cell	293
<b>APPENDIX B</b> Chemicals for cytotoxicity assay	297
<b>APPENDIX C</b> Chemicals for DNA extraction	299
<b>APPENDIX D</b> Chemicals for agarose gel electrophoresis	303
<b>APPENDIX E</b> Chemicals for cell lysates preparation	306
<b>APPENDIX F</b> Chemicals for SDS acrylamide gel electrophoresis	309
<b>APPENDIX G</b> Chemicals for western blot analysis	313
<b>APPENDIX H</b> Chemical for phytochemical group	317
<b>APPENDIX I</b> List of instrument	322
<b>CURRICULUM VITAE</b>	326

## LIST OF TABLES

<b>Table</b>		<b>Page</b>
1	Properties of human herpesviruses	5
2	Solvents used for active component extraction	52
3	Medicinal plants used in this study	82
4	Crude medicinal plant extracts after reconstitution in DMSO	110
5	Cytotoxicity doses, 50% (CD <sub>50</sub> ) values and highest non-toxic concentrations of the aqueous extracts used in this present study	116
6	Cytotoxicity doses, 50% (CD <sub>50</sub> ) and highest non-toxic concentrations of the ethanolic extracts used in this present study	118
7	Percentage of ACV inhibition on HSV-1F and HSV-2G infection	121
8	Percentage of inhibition of aqueous extracts against HSV-1F and HSV-2G and concentration of the extracts that used in this study	125
9	Percentage of inhibition of ethanolic extracts against HSV-1F and HSV-2G and concentration of the extracts that used in this study	127
10	Medicinal plant extracts and concentration used in the study	129
11	Inhibition effect of HSV infection by aqueous and ethanolic of plant extracts on before viral attachment	134
12	Inhibition effect of HSV infection by aqueous and ethanolic of plant extracts when treatment during viral attachment	138
13	Inhibition effect of HSV infection by aqueous and ethanolic of plant extracts when treatment after viral attachment	141

## LIST OF TABLES (continued)

Table		Page
14	Direct inactivation of HSV-1F by aqueous extracts	144
15	Direct inactivation of HSV-1F by ethanolic extracts	145
16	Direct inactivation of HSV-2G by aqueous extracts	146
17	Direct inactivation of HSV-2G by ethanolic extracts	147
18	Direct inactivation of HSV-1F by ethanolic extracts	151
19	Direct inactivation of HSV-2G by ethanolic extract	152
20	Percentage of HSV-1F DNA remaining after treatment with plant extracts	165
21	Percentage of HSV-2G DNA remaining after treatment with plant extracts	167
22	The percentage of HSV-1F viral protein inhibition by aqueous and ethanolic extracts of medicinal plant extract compared to viral control	172
23	The percentage of HSV-2G viral protein inhibition by aqueous and ethanolic extracts of medicinal plant extract compared to viral control	173
24	Percentage yield of fractions of <i>E. prostrata</i> by partition technique	181
25	The cytotoxicity dose, 50% (CD <sub>50</sub> ) and the highest of non-toxic concentrations of partial purified fraction isolated from ethanolic extract of <i>E. prostrata</i>	182
26	Inhibition of HSV by partial purified fractions of <i>E. prostrata</i> extract	184

## LIST OF TABLES (continued)

Table		Page
27	Percentage yield of each fraction isolated from <i>E. prostrata</i> by column chromatography using celite as stationary phase	186
28	The cytotoxicity dose, 50% (CD <sub>50</sub> ) and non-toxic concentrations of <i>E. prostrata</i> fractions	189
29	Antiviral activity of fractions of <i>E. prostrata</i> extract	191
30	Percentage yield of fractions of <i>Sphenodesme</i> sp. by partition technique	193
31	The cytotoxicity dose, 50% (CD <sub>50</sub> ) and the highest of non-toxic concentrations of partial purified fraction isolated from ethanolic extract of <i>Sphenodesme</i> sp.	194
32	Inhibition of HSV by partial purification of <i>Sphenodesme</i> sp. extract	195
33	Percentage yield recovered of each fraction isolated from <i>Sphenodesme</i> sp. extracts by column chromatography	197
34	The cytotoxicity dose, 50% (CD <sub>50</sub> ), non-toxic concentrations and color of <i>Sphenodesme</i> sp. fractions	200
35	Inhibition of HSV infection by <i>Sphenodesme</i> sp. fraction isolated from column chromatography using celite as stationary phase	203
36	Fractions and percentage yield of P107 recovered after separation by wet column chromatography	205
37	The cytotoxicity dose, 50% (CD <sub>50</sub> ) and the highest of non-toxic concentrations of each fraction isolated from P107 fraction	206

## LIST OF TABLES (continued)

Table		Page
38	Anti-HSV activity of fractions isolated from <i>Sphenodesme</i> sp. extract by column chromatography	208
39	Phytochemical groups of crude ethanolic extract and fraction of medicinal plant extracts	212
40	Major constituents of crude ethanolic extract of <i>Sphenodesme</i> sp. determined by GC-MS scan	215
41	Characteristics of herbal gel containing ethanolic extract of <i>Sphenodesme</i> sp. at concentration of 4,000 µg/ml	224
42	Characteristics of gel containing ethanolic extract of <i>Sphenodesme</i> sp. at concentration of 4,000 µg/ml after storage at 4°C for 7 months	227
43	Characteristics of gel containing ethanolic extract of <i>Sphenodesme</i> sp. at concentration of 4,000 µg/ml after storage at 25°C for 7 months	231
44	Characteristics of gel containing ethanol extract of <i>Sphenodesme</i> sp. at concentration of 4,000 µg/ml after storage at 45°C for 7 months	234
45	Irritation test of gel containing <i>Sphenodesme</i> sp. extracts in volunteers	237



## LIST OF FIGURES

Figure		Page
1	HSV genome organizations	9
2	HSV genome	10
3	Structure of HSV-1 maturation	11
4	HSV structure composed with viral DNA, icosahedral capsid, tegument and envelope	12
5	Stages of HSV initial infection	14
6	Stages of HSV reactivation	15
7	Primary and recurrent of HSV infection	16
8	HSV-1 entries into host cell	18
9	Cell surface receptors and viral glycoprotein requirement for HSV attachment and entry	20
10	Diversity of herpes simplex virus entry pathway	21
11	Replication of HSV cycle	23
12	HSV gene expressions	26
13	HSV release from infected cell	29
14	Immunology models of HSV-1 latency and reactivation	35
15	Mechanism of ACV inhibitor in HSV treatment	47
16	Mechanism of antiviral against herpes simplex virus infection	48
17	<i>Andrographis paniculata</i> (Burm.f.) Wall. ex Nees	58
18	<i>Cissus quadrangularis</i> L.	59

## LIST OF FIGURES (continued)

Figure		Page
19	<i>Cosciniium fenestratum</i> (Gaertn.) Colebr.	60
20	<i>Croton roxburghii</i> N.P. Balakr.	61
21	<i>Derris scandens</i> (Roxb.) Benth.	62
22	<i>Eclipta prostrata</i> (L.) L.	63
23	<i>Glycyrrhiza glabra</i> (L.)	64
24	<i>Gynostemma pentaphyllum</i> (Thunb.) Makino	65
25	<i>Houttuynia cordata</i> Thunb.	66
26	<i>Leptochloa chinensis</i> (L.) Nees	67
27	<i>Momordica charantia</i> Linn.	68
28	<i>Phyllanthus amarus</i> Schum.&Thonn.	69
29	<i>Pluchea indica</i> (Linn.) Less.	70
30	<i>Pseuderatherum platiferum</i> (Wall.) Radlk. ex. Lindau.	71
31	<i>Rhinacanthus nasutus</i> (Linn.) Kurz	72
32	<i>Schefflera leucantha</i> R.Vig.	73
33	<i>Senna alata</i> (Linn.) Roxb.	74
34	<i>Sphenodesme</i> sp.	75
35	<i>Stemona tuberosa</i> Lour.	76
36	<i>Stephania venosa</i> (Blume) Spreng.	77
37	<i>Thunbergia laurifolia</i> Lindl.	78
38	<i>Tinospora crispa</i> (Linn.) Miers ex Hook.f. & Thomson	79
39	<i>Zingiber montanum</i> (Koenig) Linkex Dietr.	80

## LIST OF FIGURES (continued)

Figure		Page
40	Semi-dry botting apparatus	95
41	Isolation scheme of ethanolic extract of <i>E. prostrata</i>	98
42	Isolation scheme of ethanolic extract of <i>Sphenodesme</i> sp.	99
43	Comparison of percentage yield of aqueous and ethanolic extracts of medicinal plants	112
44	Log of HSV-1F titer at 0, 1, 2, 3, 4, 5, 6, 12, 24 and 30 hours after treatment with aqueous medicinal plant extracts	154
45	Log of HSV-1F titer at 0, 1, 2, 3, 4, 5, 6, 12, 24 and 30 hours after treatment with ethnolic medicinal plant extracts	154
46	Log of HSV-2G titer at 0, 1, 2, 3, 4, 5, 6, 12, 24 and 30 hours after treatment with aqueous medicinal plant extracts	155
47	Log of HSV-2G titer at 0, 1, 2, 3, 4, 5, 6, 12, 24 and 30 hours after treatment with ethanolic medicinal plant extracts	155
48	Log of HSV-1F titer at 0, 1, 2, 3, 4, 5, 6, 12, 24 and 30 hours after treatment with ethanolic extract of <i>E.prostrata</i>	159
49	Log of HSV-1F titer at 0, 1, 2, 3, 4, 5, 6, 12, 24 and 30 hours after treatment with ethanolic extract of <i>H cordata</i>	159
50	Log of HSV-1F titer at 0, 1, 2, 3, 4, 5, 6, 12, 24 and 30 hours after treatment with ethanolic extract of <i>Sphenodesme</i> sp.	160
51	Log of HSV-2G titer at 0, 1, 2, 3, 4, 5, 6, 12, 24 and 30 hours after treatment with ethanolic extract of <i>E. prostrata</i>	161

## LIST OF FIGURES (continued)

Figure		Page
52	Log of HSV-2G titer at 0, 1, 2, 3, 4, 5, 6, 12, 24 and 30 hours after treatment with ethanolic extract of <i>H. cordata</i>	161
53	Log of HSV-2G titer at 0, 1, 2, 3, 4, 5, 6, 12, 24 and 30 hours after treatment with ethanolic extract of <i>Sphenodesme</i> sp.	162
54	Inhibitory effect of crud medicinal plant extracts at non-toxic concentration on genomic DNA of HSV-1F synthesis in Vero cells after treatment in the present of aqueous and ethanolic extracts of medicinal plant	166
55	Inhibitory effect of crud medicinal plant extracts at non-toxic concentration on genomic DNA of HSV-2G synthesis in Vero cells after treatment in the present of aqueous and ethanolic extracts of medicinal plant	168
56	Effect of <i>E. prostrata</i> extracts on HSV-1F and HSV-2G protein synthesis in Vero cells detected by Western blotting analysis in the present of aqueous and ethanolic extracts	174
57	Effect of <i>H. cordata</i> extracts on HSV-1F protein synthesis in Vero cells detected by Western blotting analysis in the present of aqueous and ethanolic extracts	175
58	Effect of <i>R. nasutus</i> extracts on HSV-1F and HSV-2G protein synthesis in Vero cells detected by Western blotting analysis in the present of aqueous and ethanolic extracts	176

## LIST OF FIGURES (continued)

Figure		Page
59	Effect of <i>Sphenodesme</i> sp. extracts on HSV-1F and HSV-2G protein synthesis in Vero cells detected by Western blotting analysis in the present of aqueous and ethanolic extracts	177
60	Effect of <i>S. tuberosa</i> extracts on HSV-1F and HSV-2G protein synthesis in Vero cells detected by Western blotting analysis in the present of aqueous and ethanolic extracts	178
61	Separation of <i>E. prostrata</i> extract by partition technique	180
62	Chromatogram of the partial purified fractions of <i>E. prostrata</i> by TLC analysis using hexane : ethyl acetate (90:10) as mobile phase when detected under wavelength at 254 and 366 nm	188
63	Separation of <i>Sphenodesme</i> sp. extract by partition technique	192
64	Chromatogram of the partial purified fractions of ethanol extract of <i>Sphenodesme</i> sp. by TLC analysis using chloroform:methanol (80:20) as mobile phase when detected under wavelength at 254 and 366 nm	198
65	Chromatogram of ethanolic extract of <i>Sphenodesme</i> sp. using GC-MS scan	215
66	HPLC-chromatograms of P107-03 fraction (254 nm)	217
67	HPLC-chromatograms of P107-03 fraction (263 nm)	217
68	HPLC-chromatograms of P107-03 fraction (366 nm)	218

## LIST OF FIGURES (continued)

Figure		Page
69	Herbal gel product and herbal gel after 6 cycles of heating-cooling cycle	223
70	Inhibitory effect of herbal gel containing ethanolic extract of <i>Sphenodesme</i> sp. against HSV-1F after heating-cooling	225
71	Inhibitory effect of herbal gel containing ethanolic extract of <i>Sphenodesme</i> sp. against HSV-2G after heating-cooling	225
72	Stability test of gel containing ethanol extract of <i>Sphenodesme</i> sp. at various concentrations (500-4,000 µg/ml) against HSV-1F after storage at 4°C for 7 months	228
73	He Stability test of gel containing ethanol extract of <i>Sphenodesme</i> sp. at various concentrations (500-4,000 µg/ml) against HSV-2G after storage at 4°C for 7 months rbal gel contained ethanolic extract of <i>S. pentandra</i> after storage for 7 months	228
74	Herbal gel contained ethanolic extract of <i>Sphenodesme</i> sp. after storage for 7 months	229
75	Stability test of gel containing ethanolic extract of <i>Sphenodesme</i> sp. at various concentrations (500-4,000 µg/ml) against HSV-1F after storage at 25°C for 7 months	232
76	Stability test of gel containing ethanolic extract of <i>Sphenodesme</i> sp. at various concentrations (500-4,000 µg/ml) against HSV-2G after storage at 25°C for 7 months	232

## LIST OF FIGURES (continued)

Figure		Page
77	Stability test of gel containing ethanolic extract of <i>Sphenodesme</i> sp. at various concentrations (500-4,000 µg/ml) against HSV-1F after storage at 45°C for 7 months	235
78	Stability test of gel containing ethanolic extract of <i>Sphenodesme</i> sp. at various concentrations (500-4,000 µg/ml) against HSV-2G after storage at 45°C for 7 months	235
79	Irritation test of herbal gel product on tested skin of volunteer	238
80	Herbal gel product containing ethanolic extract of <i>Sphenodesme</i> sp.	238

### ABBREVIATION AND SYMBOLS

%	=	Percentage
°C	=	Degree Celsius
μg	=	Microgram
μl	=	Microliter
Ab	=	Antibody
ACV	=	Acyclovir
ANOVA	=	Analysis of variance
bp	=	Base pair
BSA	=	Bovine serum albumin
CD <sub>50</sub>	=	Cytotoxic dose, 50%
cm	=	Centimeter
CMC	=	Carboxymethyl cellulose
CO <sub>2</sub>	=	Carbon dioxide
CPE	=	Cytopathic effect
DMSO	=	Dimethyl sulfoxide
DNA	=	Deoxyribonucleic acid
dsDNA	=	Double strand deoxyribonucleic acid
ED <sub>50</sub>	=	Effective dose, 50%
EDTA	=	Ethylenediamine tetra-acetic acid



EtOAc	=	Ethyl acetate
EtOH	=	Ethanol
g	=	Gram
GC	=	Gas chromatography
h	=	Hour
HPLC	=	High performance liquid chromatography
HS	=	Heparan sulfate
HSV	=	Herpes simplex virus
HSV-1	=	Herpes simplex virus type 1
HSV-2	=	Herpes simplex virus type 2
kDa	=	Kilodalton
kg	=	Kilogram
L	=	Liter
LAT	=	Latency-associated transcripts
MEM	=	Minimum essential medium
mg	=	Milligram
Min	=	Minute
ml	=	Milliliter
MOI	=	Multiplicity of infection
mRNA	=	Messenger ribonucleic acid
MS	=	Mass spectrometry
nm	=	Nanometer

No.	=	Number
PBS	=	Phosphate buffered saline
PFU/ml	=	Plaque forming unit per milliliter
RCB	=	Randomized complete blocks
R <sub>f</sub>	=	Retardation factor
RNA	=	Ribonucleic acid
rpm	=	Revolution per minute
SD	=	Standard deviation
SDS-PAGE	=	Sodium dodecyl sulfate polyacrylamide gel electrophoresis
TI	=	Therapeutic index
TLC	=	Thin layer chromatography
TNF	=	Tumor necrosis factor
UL	=	Unique long
US	=	Unique short
UV	=	Ultra violet radiation
V	=	Voltage
vhs	=	Virion host shutoff